Abbvie Inc
NYSE: ABBV
$178.64
+$1.69 (+1.0%)
Real Time Data Delayed 15 Min.
ABBV Articles
Friday's top analyst upgrades, downgrades and initiations include Harley-Davidson, Lululemon, Nike, SunPower and Walmart.
Published:
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand for the drugs they produce that treat hepatitis C.
Published:
Only one of the seven stocks traded on the New York Stock Exchange with the largest number of shares held short as of October 15 experienced a decline in short interest.
Published:
Last Updated:
UBS polled all of its analysts, who came up with 26 stocks by now. Here are the ones that offer large cap growth with the best upside.
Published:
The most shorted stocks on the New York Stock Exchange at the September 30 settlement dates saw rising short interest during the two-week period.
Published:
Short sellers shied away from Bank of American enough that it slipped out of the top five most shorted stocks on the New York Stock Exchange.
Published:
The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have created such a stir of late.
Published:
A new research report from UBS focuses on four top companies that are making great strides in treatments for patients -- and generating gigantic revenues.
Published:
Surges in short interest between the August 15 and August 29 settlement dates pushed Sprint into the top five most shorted stocks on the New York Stock Exchange.
Published:
Infinity Pharmaceuticals will partner with Abbvie to further develop and commercialize IPI-145, also known as Duvelisib.
Published:
A new report from the pharmaceutical team at Credit Suisse highlights four top stocks to buy for the remainder of 2014
Published:
AbbVie reported better-than-expected second-quarter 2014 results before markets opened Friday morning, due in part to strong sales of its Humira anti-inflammatory drug.
Published:
Last Updated:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Tuesday, July 2, 2014. They include Alcatel-Lucent, Apple, FireEye, JDSU Uniphase and solar stocks.
Published:
ThinkstockAs the summer starts, a large agenda is out there for investors when it comes to top biotech and specialty pharmaceutical companies making announcements and presenting clinical data. The...
Published:
A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is large cap pharmaceuticals. Here are their top large cap pharmaceuticals to buy now.
Published: